ABSTRACT SUBMISSION GUIDELINES

& ABSTRACT CATEGORIES

ISPAD 2026 welcomes the submission of abstracts that make an original contribution to the field. All abstracts submitted will undergo a blind peer-review process by a minimum of two members of an international review panel, with the final selection made by the Abstract Review Committee.

All accepted abstracts will be published in full in the Session Planner starting from the first day of the conference and, will also be included in an abstract eBook shortly after the conference. To have an abstract published  in the eBook, the presenting author must  register and confirm any presenter change by 3 August. Authors registering at a later date will still be able to present their abstract. Only abstracts of confirmed and registered presenters will be displayed.

gUIDELINES

The deadline for abstract submission is 11:59 pm Central European Time (CET) on April 22, 2026. Abstracts will not be accepted after this date.

All abstracts must be written in English, in “Sentence case”, and be related to pediatric and adolescent diabetes.

All abstracts must be submitted online via the abstract form accessible from your profile.

To ensure CME accreditation of oral and poster sessions, authors are asked not to mention any brand name or name of product, drug, equipment or software in the title of their abstract

The majority of accepted abstracts will be assigned to posters. A limited number of abstracts will be accepted as presentations in oral sessions

Only abstracts submitted online via the dedicated platform will be considered for presentation. It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as submitted by the author.

Please note that it is still possible to edit an abstract after having clicked on “submit”, until the submission deadline on 22 April.

The abstract text should not exceed 2,000 characters including spaces. One table/figure can be inserted, but kindly note that 50 characters per table/figure will be removed from your total abstract character count. The text of the abstract must be structured with the following headings Background, Objectives, Methods, Results and Conclusions and briefly state:

  • Background: Introduce the study to clearly highlight its relevance its relevance
  • Objectives: Indicate the purpose of the study or the hypothesis that was tested.
  • Methods: Include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. If references are needed, they should be provided in the text.
  • Results: Present as clearly as possible the outcome of the study and after significance if appropriate
  • Conclusions: Briefly discuss the data and emphasize the significance of the results. All abstracts should disclose primary findings and avoid, whenever possible, statements about ongoing or future work not presented in the abstract (future studies or results), such as “experiments are in progress” or “results will be discussed”.

 

The maximum number of characters for the title of the abstract, spaces excluded, is 200.

All abstracts should disclose primary findings and avoid statements about ongoing or future work not presented in the abstract (future studies or results, such as “experiments are in progress” or “results will be discussed”)

With the submission of an abstract to ISPAD 2026, the submitting author:

  • Accepts responsibility for the accuracy of the submitted abstract.
  • Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
  • Gives permission on behalf of all related authors for the abstract, when selected for presentation (oral or poster), to be published online by ISPAD on the conference website.

 

Criteria for abstract ineligibility

  • Abstract proposals submitted as plain texts, not being related to pediatric and adolescent diabetes , and not including the required headings (Background, Objectives, Methods, Results and Conclusions)
  • Abstracts not presenting results
  • Non-compliance with the abstract form requirements (character count, non-submitted abstract etc.)
  • Abstracts mentioning an industry related name in their title (brand name or name of product, drug, equipment or software)

 

Rule of Two

Each presenting author may present up to two abstracts at the Conference. However, there is no limit to the number of abstracts an author can submit or be listed as a co-author on.

Abstract Categories
  1. Diabetes Pathogenesis, Epidemiology and Etiology
    1. Pathogenesis & Etiology
    2. Epidemiology
  2. Genetics, Immunology and the Environment
  3. Screening/disease modification
  4. Diabetes Care
    1. Outcomes and Care Models
    2. Diabetes at School
    3. Economics and Value Addition/Access to Care
    4. Ethics of Care
    5. General Diabetes Care
  5. Diabetes Education
  6. Lifestyle, Nutrition and Exercise
  7. Diabetes Therapy and Prevention
    1. New Insulins
    2. Adjunctive Therapies
    3. Other Pharmacologic Agents
    4. Novel Advances and Interventions
  8. Technology in Diabetes Care
    1. Pumps and Continuous Glucose Monitoring (CGM)
    2. Automated Insulin Delivery, Closed loop
    3. Telemedicine, Digital Health, Decision Support and Artificial Intelligence Applications
  9. Diabetes Complications
    1. Acute Complications
    2. Chronic Complications
  10. Diabetes-Associated Diseases
  11. Childhood Obesity and Type 2 Diabetes
  12.  Monogenic and other forms of Diabetes
  13. Psychological and Psychosocial Aspects of Diabetes
  14. Diabetes in Developing Countries and Migrant Populations
  15. Other

Notification of Acceptance or Rejection

Notification of acceptance or rejection will be sent to the corresponding author (presenter) by mid-July 2026. Please note that only the corresponding author (presenter) will  be notified about the status of the abstract and will be responsible for informing all the co-authors. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.

All efforts are made to send the notifications by the planned date. Should there be any delays with the selection process, the revised date will be posted here.

Caution:

It is not allowed to submit an abstract that has been published and/or is likely to be published before the ISPAD Abstract submission deadline (April 22, 2026 23:59 CET).

The Scientific Committee reserves the right to withdraw an abstract if its data has already been published. However, ISPAD accepts abstracts that have been presented in recent months at local, national, or regional diabetes meetings (e.g., at the American Diabetes Association or European Association for the Study of Diabetes 2026 meetings).